Barosense bags $27M for obesity treatment
Barosense, maker of a device to treat obesity without invasive surgery, has brought in $27 million of a targeted $30 million fourth round of funding that it plans to use to commercialize its product, reports PE Hub. It kicked off the round in March, and said it had commitments from its existing investors.
This turned out to be true, with the Redwood City, Calif. company tapping previous backers Delphi Ventures, Frazier Healthcare Ventures, Invesco Private Capital, RWI Ventures, Synergy Life Science Partners and Wharton Ventures — as well as new investor Pappas Ventures.
The company has now raised $53 million to date, and plans to bring its device to market by the end of next year.
Next Story: MIT researchers create robotic fish for underwater exploration
Previous Story: Complete Genomics seals $45M for cheaper gene sequencing
Tags: co:Barosense, inv:Delphi-Ventures, inv:Frazier-Healthcare-Ventures, inv:Invesco-Private-Capital, inv:Pappas-Ventures, inv:RWI-Ventures, inv:Synergy-Life-Science-Partners, inv:Wharton Ventures
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.